Immune-Enhancing Therapy Improves Outcomes in Severe Pancreatitis with Metabolic Issues

Acute Necrotizing Pancreatitis (ANP) is a severe inflammatory condition with high morbidity and mortality, often complicated by systemic inflammation and infections. Patients with underlying metabolic abnormalities like diabetes or obesity face an even worse prognosis due to impaired immune responses and heightened inflammatory states. Current treatments primarily focus on supportive care, but the role of targeted immune-enhancing interventions in this specific high-risk ANP population remains underexplored.

The immune-enhancing treatment group demonstrated significantly improved clinical outcomes compared to the control group. There was a 30% reduction in the incidence of secondary pancreatic infection (p<0.01) and a 25% decrease in the occurrence of systemic inflammatory response syndrome (SIRS). The immune-enhancing treatment group exhibited a remarkable 43% reduction in 28-day mortality compared to the control group (p=0.003), indicating a substantial survival benefit. Furthermore, patients receiving immune support showed significantly lower C-reactive protein (CRP) levels by day 7 (a mean decrease of 55 mg/L vs. 20 mg/L in controls, p<0.001) and a 2.1-fold increase in lymphocyte count by day 10 (p<0.05), suggesting improved immune function.